Base editors, DNA double-strand break (DSB)-independent genome modification agents, have been recognized alongside prime editors as key technologies to watch this year, 1 and advances to date have ...

A reasonable idea, suggests Sekar Kathiresan, MD, co-founder and CEO of Verve Therapeutics, is the development of a one-time treatment—a single spelling change in the DNA of a liver gene in an adult ...